3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
1
Sarcoma
1
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Interventions
Vincristine
5
Ifosfamide
5
Etoposide
5
Radiotherapy
4
Doxorubicin
4
Cyclophosphamide
4
Dactinomycin
3
Neoadjuvant Therapy
2
Chemotherapy, Adjuvant
2
Brachytherapy
2
etoposide phosphate
1
Topotecan
1
Temozolomide
1
Mesna
1
Melphalan
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Fentanyl
1
FANG vaccine
1
Epirubicin
1
Dexrazoxane
1
Cyproheptadine
1
Carboplatin
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neuroectodermal Tumors, Primitive, Peripheral
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts